Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Ascentage Pharma Group International (OTCPK:ASPHF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Ascentage Pharma Group International's EV-to-EBIT for today is
Ascentage Pharma Group International's current Enterprise Value is $1,443.20 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $-166.31 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Ascentage Pharma Group International's EV-to-EBITDA for today is:
Ascentage Pharma Group International's current Enterprise Value is $1,443.20 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-162.83 Mil.
Ascentage Pharma Group International's current Enterprise Value is $1,443.20 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $80.88 Mil.
Ascentage Pharma Group International's current Enterprise Value is $1,443.20 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $33.38 Mil.
Ascentage Pharma Group International's current Enterprise Value is $1,443.20 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Ascentage Pharma Group International's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $32.32 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International Enterprise Value Related Terms
Ascentage Pharma Group International Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International Enterprise Value Chart
ASPHF vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Ascentage Pharma Group International's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascentage Pharma Group International Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascentage Pharma Group International's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Ascentage Pharma Group International's Enterprise Value falls into.
Ascentage Pharma Group International Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of $1,443.20 Mil mean?
Ascentage Pharma Group International (ASPHF) has a Enterprise Value of $1,443.20 Mil as of Jun. 25, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Ascentage Pharma Group International and its competitors.
Is Ascentage Pharma Group International's Enterprise Value too high?
Ascentage Pharma Group International's current Enterprise Value is $1,443.20 Mil. Overall, Ascentage Pharma Group International has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Enterprise Value compare to VRTX and REGN?
Ascentage Pharma Group International's Enterprise Value of $1,443.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Ascentage Pharma Group International and its competitors. Ascentage Pharma Group International's current Enterprise Value is $1,443.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $6.61, compared to a current price of $4.53 — trading 31.5% below its estimated fair value. The current Enterprise Value is $1,443.20 Mil. Ascentage Pharma Group International's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Enterprise Value is $1,443.20 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued.
The current stock price of $4.53 is trading 31.5% below its estimated GF Value™ of $6.61.
GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.
Key valuation signals for ASPHF:
Enterprise Value: $1,443.20 Mil
GF Value™: $6.61 vs. price of $4.53 (31.5% below fair value)
No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascentage Pharma Group International Business Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
71GF Score
Get the complete analysis for ASPHF
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASPHF has been successfully added to your 
